Inclisiran dramatically lowered PCSK9 and LDL in ORION-1 trial | ACC

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Inclisiran dramatically lowered PCSK9 and LDL among patients at high cardiovascular risk who had elevated LDL. 

Why this matters

  • Additional therapies are required for patients on statins who are at high risk for cardiovascular events. 

Key results

  • Among patients (n=...